MedTrace Logo

Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

NCT06617572 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-08-11

No results posted yet for this study

Summary

The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel). This EAP will be conducted at authorized treatment centers where TECELRA® is being administered and where the EAP is approved to be conducted. Patients who are prescribed TECELRA® , sign the informed consent form, and meet all entry criteria will be eligible to participate in this protocol.

Conditions

  • Synovial Sarcoma
  • Myxoid Liposarcoma

Interventions

GENETIC

Non-conforming afamitresgene autoleucel

Non-conforming afamitresgene autoleucel, suspension for intravenous infusion (NC afami-cel), single dose administration

Sponsors & Collaborators

  • USWM CT, LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06617572 on ClinicalTrials.gov